ABSTRACT
@#Objective: To evaluate the effect of immune cells induced and differentiated by umbilical cord blood mononuclear cells (UCMCs) on the immune function of patients with small cell lung cancer (SCLC). Methods: Ninety patients with SCLC, who were admitted to the Affiliated Hospitalof InnerMongolia Medical University from January 2012 to December 2015, were randomly divided into control group (45 patients, EP regimen), study group (45 patients, EP regimen+UCMC-induced and differentiated immune cells). The study group of patients received immune cell treatment 3-5 d after chemotherapy ([1-3]×1010cells/treatment), 30 d for a cycle. The changes in T cell subsets, IFN-γ, IL-2, IL-10 and TGF-β1 in peripheral blood of patients were observed by flow cytometry at pre-treatment and 12 weeks post-treatment. Life quality and adverse events of patients were evaluated. Results: The study group, 15 cases achieved CR, 25 cases of PR and 5 cases of SD. The percent of T cell subsets in the study group was significantly higher than that in the control group (P<0.01), and the time of return to normal level was obviously shorter (P<0.05). The serum level of inflammatory cytokine IFN-γ increased or exceeded the normal range in 80.9% patients, and IL-10 and TGF-β1 levels were significantly decreased as compared with pretreatment (P<0.05). The quality of life was obviously better than that of the control group (P<0.05). Conclusion: Immune cells induced and differentiated by UCMCs can promote the recovery of immune function of patients with SCLC.